EyePoint Pharmaceuticals Names New Members of Executive Leadership Team

Source: EyePoint Pharmaceuticals

EyePoint Pharmaceuticals announced the appointment of Scott Jones as Chief Commercial Officer and Said Saim, PhD, as Chief Technology Officer. Mr. Jones will be responsible for the commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following cataract surgery and Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye, the company’s two FDA- approved, commercially-launched ophthalmic products. Dr. Saim will be responsible for advancing EyePoint’s pipeline products and technology for ocular treatments from formulation, preclinical research up to clinical development, as well as pharmaceutical sciences, manufacturing and operations 

“Scott and Said both bring a wealth of experience and expertise in the specialty pharmaceutical industry, and we are pleased to welcome them to our growing team as we establish EyePoint’s status as a leading commercial-stage ophthalmology company,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “The launches of our two ophthalmology products have been met with strong interest from both patients and treating physicians for these debilitating eye diseases. We look forward to leveraging Scott and Said’s respective expertise to drive growth of our market share for our newly launched products and to continue the advancement of our pipeline to bring additional innovative products to market for treatments with high medical need.”

Mr. Jones brings to EyePoint significant experience commercializing drugs and devices globally. Most recently, he served as Chief Commercial Officer and Vice President, Business Development at Notal Vision, where he developed the commercial and growth strategy for the organization. Mr. Jones’ tenure at Notal Vision also included his role as President, in which he was responsible for developing a business model in the United States that would allow for a telemonitoring platform to be covered by Medicare. Before joining Notal Vision, Mr. Jones served as President of QLT Ophthalmics, where he built the strategy and infrastructure for a U.S. commercial operation. Prior to that, Mr. Jones was Executive Director, Health Policy at Novartis Pharmaceuticals, where his team was responsible for all policy issues relating to Medicare Part A, Part B and the Durable Medical Equipment Program. Mr. Jones also served as Executive Director and Head of Market Access and Government Affairs at Novartis Ophthalmics, as well as other roles of varying responsibility during his time at Novartis. Mr. Jones began his career with Geigy Pharmaceuticals as Medical Representative and subsequently as Hospital Sales Representative for Ciba-Geigy Pharmaceuticals. Mr. Jones received an M.A. in political science and a Certificate in Public Administration from the University of Florida, as well as a B.S. in chemistry. 

“My past experiences in developing revenue generating ophthalmology companies has allowed me to develop skills pertinent to understanding customer and market needs and aligning those with an effective commercial and growth strategy,” said Mr. Jones. “EyePoint’s products offer astute solutions in medical areas that have previously suffered from inconvenient and burdensome treatment options. I look forward to working with the team at EyePoint to further progress the U.S. commercial launches already underway.”  

Dr. Saim has more than 25 years of product development experience. He most recently served as Vice President, Pharmaceutical Development at Collegium Pharmaceutical, where his responsibilities included managing formulation development, clinical trial manufacturing, and commercial manufacturing for immediate, delayed and controlled release dosage forms. Prior to joining Collegium, Dr. Saim served as Senior Principal Scientist at Boehringer Ingelheim Pharmaceuticals, Inc., where he led a team of engineers and scientists in charge of process development, scale up, and technology transfer of North American products. Prior to joining Boehringer Ingelheim, Dr. Saim was Assistant Research Professor at the Higuchi BioSciences Center for Drug Delivery Research. Dr. Saim has published 22 papers in engineering and science journals and holds 18 patents. Dr. Saim earned a PhD in chemical engineering from the University of Kansas.

“EyePoint has successfully transformed into a fully-integrated, commercial-stage ophthalmology company, with two FDA-approved products now in the hands of patients and doctors in real-world settings,” Dr. Saim said. “However, EyePoint’s mission to improve ophthalmology care does not end with these launches, as the Company is equally focused on developing the balance of its pipeline to continue to deliver innovative and paradigm-changing solutions to patients suffering from eye diseases. I am thrilled to play a role in the continued expansion of EyePoint’s pipeline of ophthalmic products.”


Related Content